InsidersTradesSigma
Follow the Nuvectis Pharma, Inc. stock price and the full directors' dealings record of the company, a publicly traded company based in United States. Shares are listed on the US market, under the supervision of SEC (Form 4). Operating in the Healthcare & Pharma sector, Nuvectis Pharma, Inc. has recorded 128 insider filings. Market capitalisation: €678.4m. The latest transaction was reported on 5 August 2026 (Attribution). Among the most active insiders: BENTSUR RON. Every trade is free.
128
Insider Decl.
n/a
Thresholds
€7m
100 ops.
Buy Volume
n/a
n/a
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Nuvectis Pharma, Inc. Strong Buy (bullish), based on 5 analysts. Average price target: US$31.80.
62Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 5 August 2026
Declarations128 total
30,000 shares0Common StockSEC:0001104659-26-091279:0
12,500 sharesCommon StockSEC:0001104659-26-079792:0
Canonical exit: 28 Sept 2026 (T+90)
150,000 shares0Common StockSEC:0001104659-26-002501:0
150,000 shares0Common StockSEC:0001104659-26-002500:0
150,000 shares0Common StockSEC:0001104659-26-002497:0
61,200 shares0Common StockSEC:0001104659-26-002489:0
5,000 shares@ US$5.721.4% of flowCommon StockSEC:0001104659-25-107423:0
Canonical exit: 3 Feb 2026 (T+90)
13,000 shares@ US$5.79100.0% of flowCommon StockSEC:0001104659-25-107422:0
Canonical exit: 3 Feb 2026 (T+90)
11,000 shares@ US$5.8475.6% of flowCommon StockSEC:0001104659-25-107418:0
Canonical exit: 3 Feb 2026 (T+90)
30,000 shares0Common StockSEC:0001104659-25-104664:0
46,900 shares@ US$6.065.5% of flowCommon StockSEC:0001104659-25-103522:0
Canonical exit: 21 Jan 2026 (T+90)
5,603 shares@ US$7.990.9% of flowCommon StockSEC:0001104659-25-062168:0
Canonical exit: 18 Sept 2025 (T+90)
5,399 shares@ US$8.110.9% of flowCommon StockSEC:0001104659-25-060965:0
Canonical exit: 15 Sept 2025 (T+90)
30,000 shares0Common StockSEC:0001104659-25-058919:0
30,000 shares0Common StockSEC:0001104659-25-058916:0
30,000 shares0Common StockSEC:0001104659-25-058915:0
21,167 shares@ US$8.113.7% of flowCommon StockSEC:0001104659-25-047938:0
Canonical exit: 10 Aug 2025 (T+90)
100 shares@ US$8.990.0% of flowCommon StockSEC:0001104659-25-047089:0
Canonical exit: 6 Aug 2025 (T+90)
2,340 shares@ US$8.400.4% of flowCommon StockSEC:0001104659-25-046882:0
Canonical exit: 4 Aug 2025 (T+90)
240,000 shares@ US$5.0028.0% of flowCommon StockSEC:0001104659-25-011588:0
Canonical exit: 8 May 2025 (T+90)
150,000 shares0Common StockSEC:0001104659-25-000912:0
150,000 shares0Common StockSEC:0001104659-25-000913:0
51,000 shares0Common StockSEC:0001104659-25-000910:0
250,000 shares0Common StockSEC:0001104659-25-000909:0
4,500 shares@ US$4.650.8% of flowCommon StockSEC:0001104659-24-131541:0
Canonical exit: 24 Mar 2025 (T+90)
25 of 128 declarations
关于 Nuvectis Pharma, Inc.
Nuvectis Pharma, Inc.（股票代码：NVCT）是一家在美国纳斯达克上市的美国临床阶段生物制药公司。该公司专注于精准肿瘤学领域，该治疗领域旨在将治疗方法与特定的生物驱动因素和生物标志物定义的患者群体相匹配，而非采用一刀切的癌症治疗方法。Nuvectis于2020年7月在特拉华州注册成立，当时名为Centry Pharma, Inc.，并于2021年7月更名为Nuvectis Pharma, Inc.。其主要行政办公室位于新泽西州李堡，这表明该公司拥有一个以美国为中心的运营基地。([sec.gov](https://www.sec.gov/Archives/edgar/data/1875558/000155837025001496/tmb-20241231x10k.htm?utm_source=openai)) 该公司的商业模式围绕着专有候选药物的发现、收购和临床开发，这些药物旨在治疗具有重大未满足医疗需求的严重疾病。Nuvectis目前在其产品线中拥有两项核心临床资产。NXP900是一种口服小分子抑制剂，靶向SRC家族激酶，包括SRC和YES1。该资产被设计为1.5型抑制剂，旨在抑制SRC信号传导的催化和支架功能。根据公司披露，NXP900已完成晚期实体瘤患者的剂量递增研究以及健康志愿者的药物-药物相互作用研究，支持其作为单药治疗和与其他抗癌药物联合治疗的1b期项目。NXP800是一种激活GCN2激酶的口服小分子；它在铂耐药、ARID1A突变卵巢癌的1b期研究中显示出生物活性，公司继续评估额外的开发机会，包括通过梅奥诊所的研究者发起的胆管癌试验。([nuvectis.com](https://nuvectis.com/nxp900/?utm_source=openai)) 从竞争角度来看，Nuvectis仍然是一家纯粹的小盘生物技术公司，没有上市产品，这使得它高度依赖临床执行、融资能力以及将一个或两个项目推进到后期开发的可能性。其差异化特征是精准医疗的重点以及一支在其他生物制药公司拥有将肿瘤资产推向审批和商业发布经验的管理团队。该公司还强调了非小细胞肺癌的未来开发路径，包括与EGFR和ALK抑制剂的潜在联合策略以解决耐药机制，以及生物标志物选择的实体瘤。([nuvectis.com](https://nuvectis.com/about-us/?utm_source=openai)) 最近的发展表明NXP900持续保持发展势头。在2025年和2026年，Nuvectis报告了正在进行的1b期工作、安全性及PK/PD披露，以及在AACR和ENA等主要会议上的科学演示。该公司还在2025年12月举办了一场KOL活动，重点关注NXP900的1b期项目，强调该资产仍然是公司近期关键的价值驱动因素。([nuvectis.com](https://nuvectis.com/nxp900-publications/?utm_source=openai))
